

Nanospray Desorption Electrospray Ionization (nano-DESI) Mass Spectrometry Imaging of Drift Time-Separated Ions

Daisy Unsihuay, ruichuan yin, Daniela Mesa Sanchez, Yingju Li, Xiaofei Sun, Sudhansu Dey, Julia Laskin

Submitted date: 03/07/2020 • Posted date: 06/07/2020

Licence: CC BY-NC-ND 4.0

Citation information: Unsihuay, Daisy; yin, ruichuan; Sanchez, Daniela Mesa; Li, Yingju; Sun, Xiaofei; Dey, Sudhansu; et al. (2020): Nanospray Desorption Electrospray Ionization (nano-DESI) Mass Spectrometry Imaging of Drift Time-Separated Ions. ChemRxiv. Preprint. https://doi.org/10.26434/chemrxiv.12609536.v1

Simultaneous spatial localization and structural characterization of molecules in complex biological samples currently represents an analytical challenge for mass spectrometry imaging (MSI) techniques. In this study, we describe a novel experimental platform, which substantially expands the capabilities and enhances the depth of chemical information obtained in high spatial resolution MSI experiments performed using nanospray desorption electrospray ionization (nano-DESI). Specifically, we designed and constructed a portable nano-DESI MSI platform and coupled it with a drift tube ion mobility spectrometer-mass spectrometer (IM-MS). Separation of biomolecules observed in MSI experiments based on their drift times provides unique molecular descriptors necessary for their identification by comparison with databases. Furthermore, it enables isomer-specific imaging, which is particularly important for unraveling the complexity of biological systems. Imaging of day 4 pregnant mouse uterine sections using the newly developed nano-DESI-IM-MSI system demonstrates rapid isobaric and isomeric separation and reduced chemical noise in MSI experiments. A direct comparison of the performance of the new nano-DESI-MSI platform operated in the MS mode with the more established nano-DESI-Orbitrap platform indicates a comparable performance of these two systems. A spatial resolution of better than ~16 µm and similar molecular coverage was obtained using both platforms. The structural information provided by the ion mobility separation expands the molecular specificity of high-resolution MSI necessary for the detailed understanding of biological systems.

File list (2)

manuscript-revised.docx (2.88 MiB)	view on ChemRxiv • download file
SI.docx (1.44 MiB)	view on ChemRxiv • download file

1 Nanospray Desorption Electrospray Ionization (nano-DESI) Mass

Spectrometry Imaging of Drift Time-Separated Ions

3Daisy Unsihuay,¹ Ruichuan Yin,¹ Daniela Mesa Sanchez,¹ Yingju Li,² Xiaofei Sun,² Sudhansu K. Dey,² 4Julia Laskin¹*

- 5 1. Department of Chemistry, Purdue University, West Lafayette, IN 47907, USA
- 6 2. Division of Reproductive Sciences, Cincinnati Children's Hospital Medical Centre and
- 7 Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, OH, 45229,
- 8 USA

9Corresponding author: Julia Laskin, Tel: 765-494-5464, Email: <u>jlaskin@purdue.edu</u>

10

11 ABSTRACT

12Simultaneous spatial localization and structural characterization of molecules in complex biological 13samples currently represents an analytical challenge for mass spectrometry imaging (MSI) techniques. In 14this study, we describe a novel experimental platform, which substantially expands the capabilities and 15enhances the depth of chemical information obtained in high spatial resolution MSI experiments 16performed using nanospray desorption electrospray ionization (nano-DESI). Specifically, we designed 17and constructed a portable nano-DESI MSI platform and coupled it with a drift tube ion mobility 18spectrometer-mass spectrometer (IM-MS). Separation of biomolecules observed in MSI experiments 19based on their drift times provides unique molecular descriptors necessary for their identification by 20comparison with databases. Furthermore, it enables isomer-specific imaging, which is particularly 21important for unraveling the complexity of biological systems. Imaging of day 4 pregnant mouse uterine 22sections using the newly developed nano-DESI-IM-MSI system demonstrates rapid isobaric and isomeric 23separation and reduced chemical noise in MSI experiments. A direct comparison of the performance of 24the new nano-DESI-MSI platform operated in the MS mode with the more established nano-DESI-25Orbitrap platform indicates a comparable performance of these two systems. A spatial resolution of better 26than ~16 µm and similar molecular coverage was obtained using both platforms. The structural 27information provided by the ion mobility separation expands the molecular specificity of high-resolution 28MSI necessary for the detailed understanding of biological systems.

29

32■ INTRODUCTION

33Mass spectrometry imaging (MSI) is ideally suited for the simultaneous mapping of the spatial 34distributions of hundreds of molecules directly from tissues in a label-free fashion. ¹⁻⁶ MSI is widely used 35in biomedical research and drug discovery to obtain a better understanding of the molecular-level 36response of biological systems to different conditions. A majority of MSI applications are focused on the 37identification of biomarkers and monitoring disease progression, ⁷⁻⁹ understanding molecular alterations 38associated with organ development, ^{10,11} visualizing drug distributions in tissues to identify the 39mechanisms of their action, ^{12,13} and mapping the biological activity of enzymes by detecting their catalytic 40products. ¹⁴ Desorption electrospray ionization (DESI) ¹⁵ and matrix assisted laser desorption ionization 41(MALDI) ^{16–18} are the two most common soft ionization techniques used in MSI. Ambient ionization 42techniques like DESI have been employed in MSI experiments to eliminate sample pre-treatment prior to 43analysis and enable imaging of biological samples in their native state. Nanospray desorption electrospray 44ionization (nano-DESI) developed by our group ¹⁹ is an ambient liquid extraction-based ionization 45technique, which has been used for imaging of biological tissues with high sensitivity and high spatial 46resolution (~10 μm). ²⁰

47In the past two decades, substantial efforts have been dedicated to improving the spatial resolution, data 48processing and speed of analysis of MSI.⁵ However, on-the-fly identification of molecules in MSI 49experiments is challenging. Furthermore, the presence of some isobaric and isomeric species, which 50cannot be separated by m/z alone complicates the interpretation of MSI data necessary for an improved 51molecular-level description of complex biological systems. Some of these challenges have been addressed 52using tandem mass spectrometry (MS/MS) imaging experiments, which enable simultaneous imaging and 53identification of molecules in biological samples. However, these experiments are typically limited to 54a targeted list of m/z windows. Therefore, coupling MSI with structurally-sensitive techniques is a 55promising approach for the untargeted analysis with improved coverage and structural characterization of 56molecules in biological samples.

57Ion mobility spectrometry (IMS) separates molecules based on their size, shape and charge ^{23,24} and 58operates on a millisecond time scale making it easy to integrate into MSI experiments. ^{25,26} Furthermore, 59drift tube ion mobility spectrometry (DTIMS) provides the structural information in the form of collision 60cross sections (CCS) of the separated ions. ^{27–29} An interlaboratory study has demonstrated that CCS values 61are reproducible across different experimental platforms, ³⁰ which makes them excellent molecular 62descriptors and enables confident annotations of numerous biomolecules using open-source databases. ^{31–33}

63Several ion mobility instruments have been successfully coupled with MSI techniques including 64MALDI,^{34,35} DESI,^{36,37} liquid extraction surface analysis (LESA),³⁸ laser desorption electrospray ionization 65(LAESI)³⁹ and infrared matrix-assisted laser desorption electrospray ionization (IR-MALDESI).⁴⁰ The 66advantages of such coupling include an improved molecular coverage and sensitivity, the ability to 67generate background-free images, and rapid isomeric separation.^{25,41}

68Herein, we describe the design and performance of a portable high-resolution nano-DESI imaging 69platform coupled to a linear ion mobility quadrupole time-of-flight mass spectrometer (IM-QTOF MS), 70which enables imaging of drift time-separated ions. Proof-of-concept MSI experiments using mouse 71uterine sections demonstrate the capabilities of this newly-developed platform for imaging of drift time-72selected biomolecules with a spatial resolution ranging from 16 to 25 μm. In combination with the 73previously reported quantitative capabilities of nano-DESI MSI, this platform opens up new research 74directions focused on isomer-selected quantitative imaging of complex biological samples. Furthermore, 75the newly developed versatile platform can be coupled to any type of a mass spectrometer making it 76broadly applicable to a variety of applications.

77

78 EXPERIMENTAL SECTION

79Chemicals.

80Lysophosphatidylcholine (LPC 19:0) was purchased from Avanti Polar Lipids (Alabaster, AL). LC-MS 81grade methanol (MeOH) and water were purchased from Sigma-Aldrich (St. Louis, MO).

82Tissue Samples.

83Uterine tissues on day 4 of pregnancy were retrieved from mice on a C57/BL6 mixed background as 84described in our previous studies. The mice were housed in the Cincinnati Children's Hospital Medical 85Center Animal Care Facility according to National Institutes of Health and institutional guidelines for the 86use of laboratory animals and animal handling protocols of the approved by Cincinnati Children's 87Hospital Research Foundation Institutional Animal Care and Use Committee. Uterine tissues on day 4 of 88pregnancy were snap-frozen and sectioned using a cryostat. Sections of 12 µm thickness were mounted 89onto glass slides and stored in a -80 C freezer prior to analysis.

90Instrument description:

91Nano-DESI MSI experiments were performed on an Agilent 6560 IM-QTOF MS (Agilent Technologies, 92Santa Clara, CA) and Q-Exactive HF-X Orbitrap mass spectrometer (Thermo Fisher Scientific, Waltham,

93MA). A custom-designed nano-DESI platform employed in the nano-DESI-Orbitrap experiments has 94been described in detail elsewhere.^{43–46} Typical source conditions of the Q-Exactive HF-X are as follows: 95ESI voltage of +3.2 kV, capillary temperature of 250 °C, funnel RF level of 100.

96A schematic of the nano-DESI source is shown in **Figure 1a**. **Figures 1b** and **1c** show the nano-DESI 97imaging system developed in this study which is assembled on a portable cart (1) that can be readily 98deployed in combination with any mass spectrometer. The cart houses all the components including a 99vibrationally insulated platform (2) (Newport, Irvine, CA), a lock-in amplifier (3) (Stanford Research 100Systems, Sunnyvale, CA) and a computer that controls the system (4). The XYZ stage (5) and sample 101holder are mounted on the vibrationally insulated platform, along with the micro-positioners (6) and 102Dino-Lite cameras (7). A stainless steel capillary extension (8) is attached to the mass spectrometer inlet 103as shown in **Figure 1c**. The nano-DESI probe is described in the next section. A pulse of 5V to 0V 104provided by the LabView program is used to synchronize the XYZ stage and Agilent's acquisition 105software. Typical source parameters are as follows: ESI voltage of +4.5 kV, capillary temperature of 300 106°C. Manual tuning was carried out to optimize the front funnel and rear funnel parameters in MS mode 107and IM mode. The detailed instrument settings can be found in **Tables S1-S3**. For nano-DESI IM-QTOF 108experiments, trapping time and release time were set to 15 ms and 150 μs, respectively.

109Nano-DESI MSI:

110Imaging experiments were performed using a mixture of MeOH:H₂O (9:1) (v/v), which was infused using 111a syringe pump (KD Scientific, Holliston, MA) at 0.5 μL/min. The high-resolution nano-DESI probe is 112assembled in front of the mass spectrometer inlet as shown in Figure 1 and described in our previous 113studies. 43,46 Briefly, the finely pulled primary (9) and spray (10) capillaries with OD of 15-25 µm are 114aligned to form a liquid bridge. Analyte molecules are extracted into the liquid bridge directly from the 115tissue and transferred to a mass spectrometer inlet through the spray capillary. A third capillary (11), that 116serves as a shear-force probe, 46 is positioned in close proximity to the nano-DESI probe to maintain a 117constant distance between the sample and the nano-DESI probe. Mass spectra are acquired in positive 118 mode in the range of m/z 133–2000. Imaging data are acquired in lines by scanning the sample under the 119nano-DESI probe in one direction and stepping between the lines in another direction. For all the data 120reported in this study, we used a scan rate of 20 μm/s and a step between the lines of 29 μm resulting in a 121total analysis time of \sim 3 h per tissue section (\sim 4 mm²). To compare the performance of the nano-DESI-122Orbitrap with nano-DESI-IM-QTOF operated in the MS mode, we used an acquisition rate of 7 Hz 123 resulting in an average pixel size of $2.9 \times 29 \mu m^2$. Another series of experiments was performed to 124compare between IM-QTOF and QTOF data using an acquisition rate of 1 Hz resulting in an average 125pixel size of $20 \times 29 \mu m^2$.

126Data processing

127[M+Na]⁺ and [M+K]⁺ ions are the most abundant species in positive mode nano-DESI MSI of biological 128tissues. The initial lipid and metabolite identifications are performed based on the accurate mass 129measurement using LIPID MAPS (www.lipidmaps.org) and METLIN (https://metlin.scripps.edu). The 130final assignments are confirmed using MS/MS data collected over the tissue immediately after every 131imaging experiment using data-dependent acquisition (or auto MS/MS for QTOF). Moreover, the 132presence of multiple adducts of the same molecule is used to validate the assignments especially for the 133small metabolites, for which it is often difficult to find MS/MS spectra of alkali metal adducts in the 134literature.

135Analysis of the nano-DESI-Orbitrap data is performed using the Peak-by-Peak software (Spectroswiss, 136Lausanne, Switzerland) that employs parallel (multi-core) calculations. A three-point quadratic 137interpolation to determine the apex of the peak is used to extract peaks from mass spectra. The abundance 138of selected m/z features in each pixel (mass spectrum) is normalized to the total ion current (TIC) and 139plotted as a function of the location on the tissue sample to generate ion images using a mass tolerance 140window of ± 10 ppm.

141Analysis of the QTOF data is performed using the Ion Mobility-Mass Spectrometry Image Creator script 142developed by our group. 47 Though there is no ion mobility information in some of the current experiment 143unlike described in the original publication, the workflow still functions in the same fashion. In brief, the 144script interfaces with Skyline's 48 command line to input raw data files and export a chronogram summary 145of targeted masses. The script then reconstructs those chronograms into individual ion images. The 146resulting images use a self-normalized heat map color scale. Intensity values for each pixel are 147normalized to the TIC. For QTOF data, the mass list used to generate ion images are obtained using the 148peak list from averaged MS spectra of all lines. For data with mobility information, Agilent's MassHunter 149Mass Profiler software is used to extract a feature list, i.e. a list containing m/z, drift time, and charge 150information of recurring peaks among all experiment lines.

151■ RESULTS AND DISCUSSION

152Herein, we describe the implementation of high-resolution nano-DESI MSI on an Agilent 6560 IM-QTOF 153system. We evaluate the performance of nano-DESI-QTOF MSI by comparing the results obtained using 154the IM-QTOF system operated in the MS mode with the results obtained using the nano-DESI-Orbitrap 155system described in our previous studies. ^{43,49} Furthermore, we demonstrate the capabilities of nano-DESI 156MSI in combination with IM separation, which enables both m/z- and ion mobility-selected imaging of 157molecules in tissues.

158Comparison of High-Resolution Nano-DESI MSI Performed on the QTOF and Orbitrap Systems.

159**Figure 2a** shows representative mass spectra in the m/z range 700-900 acquired using nano-DESI-OTOF 160(top panel) and nano-DESI-Orbitrap (bottom panel). The spectra are averaged over a line scan 161corresponding to the central region of the uterine tissue. We observe that regardless of the platform used, 162phosphatidylcholine (PC) species are the dominant peaks in the m/z range 700-900 of uterine tissue in 163 positive mode nano-DESI MSI. The major difference between the two spectra is the relative abundance of 164[M+Na]⁺ and [M+K]⁺ ions. Specifically, [M+Na]⁺ ions are more dominant in the Orbitrap spectrum, 165whereas [M+K]+ ions are more abundant in the QTOF spectrum. However, the same PC species are 166 observed in both spectra. We attribute this difference to the variability between the tissue sections, which 167may have been collected from different regions of the uterine tissue. Alternatively, different rates of 168solvent evaporation from charged droplets in the heated inlets may affect the relative abundance of alkali 169metal adducts. For the purpose of comparison between the two nano-DESI platforms, we included only 170 one adduct into the final count of the observed species. MS/MS data collected on the same tissue section 171after every imaging experiment, revealed the presence of isobaric compounds which could not be 172 resolved neither by the Orbitrap (m/ Δ m = 46,369 at 400.3415 and m/ Δ m = 34,474 at m/z 782.5653) nor 173by the QTOF (m/ Δ m = 20,636 at m/z 400.3415 and m/ Δ m = 23,465 at m/z 782.5653). Therefore, it is 174expected that ion images obtained for these peaks contain contributions from several overlapping species. 175Recently, it has been demonstrated that separation of the isobaric species can be improved using a Fourier 176transform ion cyclotron resonance mass spectrometer, an instrument, which has mass resolution far 177superior to the mass spectrometers employed in this work.⁵⁰ Alternatively, MS/MS imaging has been 178shown to separate isobaric species based on the unique fragments.²²

179Using nano-DESI MSI in positive mode, we have successfully detected 119 unique lipids across 15 lipids 180subclasses and 50 metabolites for a total of 169 identifications in mouse uterine tissue sections (**Figure 1812b**). A complete list of the annotated species can be found in **Table S4**. PCs are by far the most abundant 182lipid subclass with the highest number of species (33 species), followed by PC plasmalogens (14 species) 183and diacylglycerols (DG, 14 species). Out of the 169 unique molecules identified, 158 species were 184detected with the Orbitrap and 148 with QTOF (**Figure 2c**). The main difference in the coverage 185displayed by these two platforms is in the number of phosphatidylethanolamine (PE) species, which is 186greater in the Orbitrap (13 species) than QTOF (3 species) data. PEs are zwitterionic compounds that can 187ionize in both positive and negative mode. However, they are not very abundant and are highly 188suppressed by PC species in positive mode. However, they are not very abundant and are highly 189the higher mass resolution of the Orbitrap, which helps resolve isobaric PE from PC species. For 190example, two neighboring ions at *m*/*z* 818.5637 and 818.6019 were identified as sodiated PE(40:4) and

191PC(P-38:3), respectively. Separation of species with a mass difference of 0.0364 Da corresponding to the 192difference between CH_4 and O, requires a mass resolution of 33,000 at m/z 818.6019. This condition was 193met on the Orbitrap but not QTOF, which was operated in the extended dynamic range (2 GHz) mode. 194Therefore, a broad peak at m/z 818.6015 was observed in the QTOF spectrum and was counted as PC(P-19538:3), which excluded the isobaric PE(40:4) from the count.

196Figure 3 shows nano-DESI ion images collected using the Orbitrap (bottm row) and QTOF (top row) 197along with the optical images of the corresponding tissue sections. Different parts of the uterine section 198including myometrium (Myo), stroma (S), luminal epithelium (LE) and glandular epithelium (GE) are 199indicated in the optical image. Representative ion images of endogenous molecules highlight different 200patterns of region-specific molecular distributions observed in uterine tissue sections. For example, ion 201 images corresponding to monoglyceride (MG) (18:1) and sphingomyelin (SM) (d34:1) display a 202substantial enhancement in the LE and GE cells. Meanwhile, a complementary distribution is observed 203for LPC(18:0) and PC(32:0) which are depleted in both LE and GE. A slight enhancement only in GE is 204observed for PC(36:5) and PC(36:4), whereas an enhancement only in LE is observed for PC(38:2). Most 205metabolites such as carnitine display a less delineated distribution and are distributed across stroma, LE, 206and GE. Finally, some molecules such as LPC(18:1) are evenly distributed across the entire tissue. Ion 207 images of uterine tissue sections generated using the newly developed nano-DESI platform coupled to the 208QTOF, exhibit the same image quality and are in close agreement with the ion distributions obtained 209using the nano-DESI-Orbitrap system. Moreover, a spatial resolution of 15.8 µm was calculated for 210QTOF ion images, which is comparable to the spatial resolution of 16.1 µm displayed by the Orbitrap ion 211images (Figure S1). These results demonstrate the successful implementation of the high-resolution 212nano-DESI MSI on the IM-QTOF providing a path for obtaining high-quality ion images of drift time-213separated species described in the next section. Furthermore, the portable platform presented herein 214enables the implementation of nano-DESI MSI on any commercial mass spectrometer. Indeed, we were 215able to use this platform in combination with an ion trap mass spectrometer in our laboratory.

216Nano-DESI MSI of Drift Time-Separated Ions

217In another experiment, we operated the IM-QTOF instrument in the IM-MS mode to enable IM separation 218of ions during nano-DESI MSI experiments. Nano-DESI IM-MSI experiments were performed using 219mouse uterine sections with an acquisition rate of 1 Hz. For comparison, nano-DESI-MSI experiments 220were conducted using the same acquisition rate of 1 Hz.

221Figure 4a shows the results of the positive mode nano-DESI molecular profiling obtained with and 222without the IM separation. A larger number of species was detected in the MS mode (146 species) than in

223the IM-MS mode (131 species). We attribute the difference in coverage between the two modalities to the 224overall loss in signal intensity in the IM-MS mode by about an order of magnitude in comparison with the 225MS mode. As a result, some low-abundance species including SM, MG, fatty acids (FA), and several 226metabolites were not detected in the IM-MS mode. Multiplexing strategies have proven to improve both 227the duty cycle and sensitivity of DTIMS systems. ^{52–54} We anticipate that a substantial improvement in the 228signal of low-abundant species and molecular coverage may be achieved by incorporating multiplexing 229into IM-MSI experiments.

230**Figure 4b** displays drift time-separated ion images obtained for molecules in mouse uterine sections. The 231corresponding ion images obtained in the MS mode are shown for comparison. There is a good 232correspondence between the drift time-selected ion images and ion images obtained in the MS mode for 233the corresponding *m/z*. A slightly lower spatial resolution was obtained in both MS mode (23.4μm) and 234IM-MS modes (25.3 μm) with an acquisition rate of 1 Hz in comparison to the results obtained at 7 Hz 235owing to the smaller number of mass spectra collected in a line scan (**Figure S1**). Indeed, we found that 236the sharpest chemical gradients in the 1 Hz data correspond to 1-2 pixels indicating that the spatial 237resolution in this experiment is determined by the acquisition rate rather than the size of the liquid bridge. 238However, as shown in **Figure S2**, the S/N ratio at 782.5655 is improved at slower acquisition rates from 239915 at 7 Hz to 1699 at 1 Hz due to an increase in the number of mass spectra averaged per pixel.

240**Figure** 5a shows the drift time vs. *m*/*z* plot of all the species identified in the mouse uterine tissue in 241nano-DESI-IM-MSI experiments. An expanded view of the m/z 760-880 range shown in Figure 5b 242demonstrates how these molecules are grouped into different chemical families based on their drift times 243(DT). For each adduct type and lipid class indicated by different markers and colors in Figure 5b, we 244observe distinct homologous series of species differing by the number of double bonds. Each of these 245series is highlighted with a colored line and labeled using the AA:X notation, in which AA indicates the 246acyl chain length containing X double bonds. The number of double bonds in each species is indicated 247inside the corresponding marker in the plot. In order to simplify the information provided in **Figure 5b**, 248we removed protonated species as they showed overlapping trend lines with sodium adducts within the 249same class. A complete drift time vs. m/z plot, in which all the adducts are included is presented in 250Figure S3. Structural differences pertaining to the lipid class and type of adduct are easy to visualize 251based on the DT separation. For example, it is relatively easy to distinguish different adducts of PC and 252PE species of varying length of fatty acyl tails. We observe that for the same length of acyl chains, PE 253species are characterized by shorter DTs indicating a better packing efficiency of these molecules in 254comparison to PCs. 55 Moreover, DT separation highlights structural changes within the same homologous 255series of species. For example, for the same lipid class, type of adduct, and acyl chain length, DTs 257the acyl chain which makes the molecule more compact and enables it to travel faster within the drift cell. 258These observations are consistent with the results reported in the literature ^{56,57} and highlight the power of 259IM separation for the identification of compounds observed in MSI experiments based on the predictable 260differences in the trend lines exhibited by every lipid class. Moreover, the ability to calculate CCS values 261directly from DT values is an advantage that will be exploited in future studies to improve the confidence 262of molecular annotations.

263Detailed analysis of the IM-MSI data highlight several promising capabilities enabled by the nano-DESI-264IM-QTOF platform. First, the ability to perform rapid isomeric differentiation on a time scale compatible 265with MSI experiments is critical to understanding the localization of isomeric species, which cannot be 266separated in MS mode. A representative 2D IM-MS plot for the *m*/z 325.1-325.3 window is shown in 267**Figure S4**. We observe the presence of two isomeric components at *m*/z 325.2108, which are readily 268separated by their DT. Ion images generated for these two components indicate different localization of 269the isomeric species in the tissue. The molecule at DT 25.87 ms is slightly enhanced in LE whereas the 270molecule at DT 26.83 ms is evenly distributed across the tissue. Although the identification of these 271species is beyond the scope of this paper, this result clearly illustrates that IM separation enables spatial 272localization of isomeric species. In combination with the structural information, which cannot be inferred 273from the accurate mass measurement alone, this capability is particularly advantageous for molecular-274level understanding of biological processes.

275Although some PC and PE species were not separated in the MS mode under the experimental conditions 276used in this study, they were readily separated in the IM mode. **Figure S5** shows a 2D IMS-MS map for 277the *m*/z 818.4-818.7 window where the peaks at *m*/z 818.5617 and *m*/z 818.6011, which are not separated 278in the MS mode, are observed as two distinct features in the DT dimension. As a result, the number of PE 279species, for which ion images could be generated increased from 3 in the MS mode to 11 in the IM-MS 280mode (**Figure 4a**). This indicates that IM separation relaxes the constraints imposed on the mass 281resolving power of a mass spectrometer making MSI experiments more accessible to the scientific 282community. Previously, the isobaric differentiation in IM-MSI was used to distinguish between isobaric 283peptides fragments corresponding to tubulin and ubiquitin.⁵⁸ The reconstructed ion images of these 284proteins showed remarkably different distributions in rat brain tissue sections.

285Another advantage provided by the IM separation is that it helps eliminate interferences from solvent 286peaks in nano-DESI MSI. **Figure S6** illustrates the separation of LPC(18:2) as a $[M+Na]^+$ ion at m/z 287542.3208 from an isobaric solvent peak at m/z 542.2983. It can be clearly observed that the spatial 288distribution of LPC(18:2) is completely masked by the background peak in the MS mode. Meanwhile, a

289distinct pattern showing that this molecule is depleted in both LE and GE is observed in the IM-MS 290mode. This capability has been previously used in MALDI-IMS-MSI experiments to obtain high-quality 291ion images of endogenous lipids in breast tumor tissue by reducing the interference from matrix ions.⁵⁹

292 CONCLUSION

293In this work, we expanded the analytical capabilities of nano-DESI MSI by successfully coupling it with 294ion mobility separation, which opens up new opportunities for the spatially-resolved analysis of complex 295biological samples. A new high-resolution nano-DESI source was developed, and its performance was 296evaluated in terms of coverage and quality of the obtained ion images. Using mouse uterine tissue as a 297model system, we demonstrate that similar molecular coverage, image quality, and spatial resolution are 298achieved using the new nano-DESI-QTOF platform and nano-DESI Orbitrap used in our previous studies. 299Moreover, the newly developed nano-DESI platform is portable and can be interfaced with any 300commercial mass spectrometer. Nano-DESI-IM-MSI experiments provide mass- and drift time-selected 301ion images of uterine sections with high spatial resolution. Coupling of ion mobility separation with nano-302DESI MSI improves the separation of both isobaric and isomeric species thereby increasing the molecular 303specificity of imaging experiments. Moreover, drift time separation eliminates the unwanted contribution 304of background peaks to the observed ion images of endogenous molecules extracted from the sample. 305Future studies will focus on improving sensitivity of the IM-MSI experiments to enable the detection of 306low-abundance species. This can be achieved using multiplexing strategies, which improve the sensitivity 307 of IM experiments at no expense of the throughput. Our first proof-of-concept experiments indicate that 308the new nano-DESI-IM-MSI platform improves the depth of structural information of interest to 309biological and clinical research.

310■ ACKNOWLEDGMENTS

311This research is supported by the grant from the National Science Foundation (NSF-1808136, JL) and 312National Institute of Health (HD068524, SKD). DMS acknowledges support from the National Science 313Foundation Graduate Research Fellowship under Grant No. (DGE-1333468). Any opinions, findings, and 314conclusions or recommendations expressed in this material are those of the authors and do not necessarily 315reflect the views of the NSF or NIH. We would like to thank to Pei Su, Dr. Ruwan T. Kurulugama, and 316Dr. John Fjeldsted for their technical assistance with the QTOF instrument and data analysis workflow 317used in this study.

318■ ASSOCIATED CONTENT

319Supporting Information. The Supporting Information is available free of charge on the ACS Publications 320website.

321 AUTHOR INFORMATION

322Corresponding Author

323*Phone: 765-494-5464. E-mail: <u>ilaskin@purdue.edu</u>

324Notes

325The authors declare no competing financial interest.

326 REFERENCES

- 327(1) Stoeckli, M.; Chaurand, P.; Hallahan, D. E.; Caprioli, R. M. Nat. Med. 2001, 7, 493–496.
- 328(2) Wu, C.; Dill, A. L.; Eberlin, L. S.; Cooks, R. G.; Ifa, D. R. Mass Spectrom. Rev. 2013, 32 (3), 218–
- 329 243.
- 330(3) Nilsson, A.; Goodwin, R. J. A.; Shariatgorji, M.; Vallianatou, T.; Webborn, P. J. H.; Andrén, P. E.
- 331 Anal. Chem. **2015**, 87, 1437–1455.
- 332(4) Lanni, E. J.; Rubakhin, S. S.; Sweedler, J. V. J. Proteomics **2012**, 75 (16), 5036–5051.
- 333(5) Buchberger, A. R.; DeLaney, K.; Johnson, J.; Li, L. Anal. Chem. 2018, 91 (8), 240–265.
- 334(6) McDonnell, L. A.; Heeren, R. M. A. Mass Spectrom. Rev. 2007, 26 (4), 606–643.
- 335(7) Tsubata, Y.; Hayashi, M.; Tanino, R.; Aikawa, H.; Ohuchi, M.; Tamura, K.; Fujiwara, Y.; Isobe, T.;
- 336 Hamada, A. Sci. Rep. 2017, 7, 12622.
- 337(8) Jarmusch, A. K.; Pirro, V.; Baird, Z.; Hattab, E. M.; Cohen-Gadol, A. A.; Cooks, R. G. Proc. Natl.
- 338 Acad. Sci. U. S. A. **2016**, 113 (6), 1486–1491.
- 339(9) Lanekoff, I.; Cha, J.; Kyle, J. E.; Dey, S. K.; Laskin, J.; Burnum-Johnson, K. E. Sci. Rep. 2016, 6,
- 340 33023.
- 341(10) Garikapati, V.; Karnati, S.; Bhandari, D. R.; Baumgart-Vogt, E.; Spengler, B. Sci. Rep. 2019, 9,
- 342 3192.
- 343(11) Dautel, S. E.; Kyle, J. E.; Clair, G.; Sontag, R. L.; Weitz, K. K.; Shukla, A. K.; Nguyen, S. N.;
- Kim, Y. M.; Zink, E. M.; Luders, T.; Frevert, C. W.; Gharib, S. A.; Laskin, J.; Carson, J. P.; Metz,
- 345 T. O.; Corley, R. A.; Ansong, C. Sci. Rep. 2017, 7, 40555.
- 346(12) Bruinen, A. L.; Van Oevelen, C.; Eijkel, G. B.; Van Heerden, M.; Cuyckens, F.; Heeren, R. M. A.
- 347 *J. Am. Soc. Mass Spectrom.* **2016**, *27* (1), 117–123.
- 348(13) Rao, T.; Shao, Y.; Hamada, N.; Li, Y.; Ye, H.; Kang, D.; Shen, B.; Li, X.; Yin, X.; Zhu, Z.; Li, H.;
- 349 Xie, L.; Wang, G.; Liang, Y. Anal. Chim. Acta 2017, 952, 71–80.
- 350(14) Hamilton, B. R.; Marshall, D. L.; Casewell, N. R.; Harrison, R. A.; Blanksby, S. J.; Undheim, E.
- 351 A. B. Angew. Chemie Int. Ed. **2020**, 59, 3855–3858.

- 352(15) Eberlin, L. S.; Ferreira, C. R.; Dill, A. L.; Ifa, D. R.; Cooks, R. G. Biochim. Biophys. Acta Mol.
- 353 *Cell Biol. Lipids* **2011**, *1811* (11), 946–960.
- 354(16) Spengler, B. Anal. Chem. **2015**, 87 (1), 64–82.
- 355(17) Gode, D.; Volmer, D. A. Analyst **2013**, 138 (5), 1289–1315.
- 356(18) Cornett, D. S.; Reyzer, M. L.; Chaurand, P.; Caprioli, R. M. Nat. Methods 2007, 4, 828–833.
- 357(19) Roach, P. J.; Laskin, J.; Laskin, A. Analyst **2010**, *135*, 2233–2236.
- 358(20) Laskin, J.; Heath, B. S.; Roach, P. J.; Cazares, L.; Semmes, O. J. *Anal. Chem.* **2012**, *84* (1), 141–359 148.
- 360(21) Burnum, K. E.; Cornett, D. S.; Puolitaival, S. M.; Milne, S. B.; Myers, D. S.; Tranguch, S.; Brown, H. A.; Dey, S. K.; Caprioli, R. M. *J. Lipid Res.* **2009**, *50* (11), 2290–2298.
- 362(22) Lanekoff, I.; Burnum-Johnson, K.; Thomas, M.; Short, J.; Carson, J. P.; Cha, J.; Dey, S. K.; Yang, P.; Prieto Conaway, M. C.; Laskin, J. *Anal. Chem.* **2013**, *85* (20), 9596–9603.
- 364(23) Paglia, G.; Astarita, G. Nat. Protoc. 2017, 12, 797–813.
- 365(24) Dodds, J. N.; Baker, E. S. J. Am. Soc. Mass Spectrom. 2019, 30 (11), 2185–2195.
- 366(25) Kiss, A.; Heeren, R. M. A. Anal. Bioanal. Chem. 2011, 399, 2623–2634.
- 367(26) Sans, M.; Feider, C. L.; Eberlin, L. S. Curr. Opin. Chem. Biol. 2018, 42, 138–146.
- 368(27) May, J. C.; Goodwin, C. R.; Lareau, N. M.; Leaptrot, K. L.; Morris, C. B.; Kurulugama, R. T.;
- 369 Mordehai, A.; Klein, C.; Barry, W.; Darland, E.; Overney, G.; Imatani, K.; Stafford, G. C.;
- 370 Fjeldsted, J. C.; McLean, J. A. Anal. Chem. 2014, 86 (4), 2107–2116.
- 371(28) Bowers, M. T. Int. J. Mass Spectrom. 2014, 370, 75–95.
- 372(29) Bohrer, B. C.; Merenbloom, S. I.; Koeniger, S. L.; Hilderbrand, A. E.; Clemmer, D. E. *Annu. Rev. Anal. Chem.* **2008**, *1*, 293–327.
- 374(30) Stow, S. M.; Causon, T. J.; Zheng, X.; Kurulugama, R. T.; Mairinger, T.; May, J. C.; Rennie, E. E.;
- 375 Baker, E. S.; Smith, R. D.; McLean, J. A.; Hann, S.; Fjeldsted, J. C. Anal. Chem. 2017, 89 (17),
- 376 9048–9055.
- 377(31) Picache, J. A.; Rose, B. S.; Balinski, A.; Leaptrot, K. L.; Sherrod, S. D.; May, J. C.; McLean, J. A. *Chem. Sci.* **2019**. *10*, 983–993.
- 379(32) Zheng, X.; Aly, N. A.; Zhou, Y.; Dupuis, K. T.; Bilbao, A.; Paurus, V. L.; Orton, D. J.; Wilson, R.; 380 Payne, S. H.; Smith, R. D.; Baker, E. S. *Chem. Sci.* **2017**, *8*, 7724–7736.
- 381(33) Plante, P. L.; Francovic-Fontaine, É.; May, J. C.; McLean, J. A.; Baker, E. S.; Laviolette, F.;
- 382 Marchand, M.; Corbeil, J. Anal. Chem. 2019, 91 (8), 5191–5199.
- 383(34) Jackson, S. N.; Ugarov, M.; Egan, T.; Post, J. D.; Langlais, D.; Schultz, J. A.; Woods, A. S. *J. Mass Spectrom.* **2007**, *42* (8), 1093–1098.
- 385(35) Spraggins, J. M.; Djambazova, K. V.; Rivera, E. S.; Migas, L. G.; Neumann, E. K.; Fuetterer, A.;
- 386 Suetering, J.; Goedecke, N.; Ly, A.; Van De Plas, R.; Caprioli, R. M. Anal. Chem. 2019, 91 (22),
- 387 14552–14560.
- 388(36) Feider, C. L.; Elizondo, N.; Eberlin, L. S. Anal. Chem. 2016, 88 (23), 11533–11541.

- 389(37) Bennett, R. V.; Gamage, C. M.; Galhena, A. S.; Fernández, F. M. *Anal. Chem.* **2014**, *86* (8), 3756–390 3763.
- 391(38) Griffiths, R. L.; Hughes, J. W.; Abbatiello, S. E.; Belford, M. W.; Styles, I. B.; Cooper, H. J. *Anal. Chem.* **2020**, *92* (4), 2885–2890.
- 393(39) Shrestha, B.; Vertes, A. Anal. Chem. **2014**, 86 (9), 4308–4315.
- 394(40) Ekelöf, M.; Dodds, J.; Khodjaniyazova, S.; Garrard, K. P.; Baker, E. S.; Muddiman, D. C. *J. Am. Soc. Mass Spectrom.* **2020**, *31* (3), 642–650.
- 396(41) Sans, M.; Feider, C. L.; Eberlin, L. S. Curr. Opin. Chem. Biol. 2018, 42, 138–146.
- 397(42) Lanekoff, I.; Burnum-Johnson, K.; Thomas, M.; Cha, J.; Dey, S. K.; Yang, P.; Prieto Conaway, M. C.; Laskin, J. *Anal. Bioanal. Chem.* **2015**, *407* (8), 2063–2071.
- 399(43) Yin, R.; Burnum-Johnson, K. E.; Sun, X.; Dey, S. K.; Laskin, J. *Nat. Protoc.* **2019**, *14* (12), 3445–400 3470.
- 401(44) Lanekoff, I.; Heath, B. S.; Liyu, A.; Thomas, M.; Carson, J. P.; Laskin, J. *Anal. Chem.* **2012**, *84* 402 (19), 8351–8356.
- 403(45) Nguyen, S. N.; Sontag, R. L.; Carson, J. P.; Corley, R. A.; Ansong, C.; Laskin, J. *J. Am. Soc. Mass* 404 *Spectrom.* **2018**, *29* (2), 316–322.
- 405(46) Nguyen, S. N.; Liyu, A. V.; Chu, R. K.; Anderton, C. R.; Laskin, J. *Anal. Chem.* **2017**, *89* (2), 406 1131–1137.
- 407(47) Mesa Sanchez, D.; Creger, S.; Singla, V.; Kurulugama, R. T.; Fjeldsted, J.; Laskin, J. *J. Am. Soc.*408 *Mass Spectromety submitted*.
- 409(48) MacLean, B.; Tomazela, D. M.; Shulman, N.; Chambers, M.; Finney, G. L.; Frewen, B.; Kern, R.;
 410 Tabb, D. L.; Liebler, D. C.; MacCoss, M. J. *Bioinformatics* 2010, *26* (7), 966–968.
- 411(49) Yin, R.; Kyle, J.; Burnum-Johnson, K.; Bloodsworth, K. J.; Sussel, L.; Ansong, C.; Laskin, J. *Anal. Chem.* **2018**, *90* (11), 6548–6555.
- 413(50) Bowman, A. P.; Blakney, G. T.; Hendrickson, C. L.; Ellis, S. R.; Heeren, R. M. A.; Smith, D. F. **2020**, *92* (4), 3133–3142.
- 415(51) Boskamp, M. S.; Soltwisch, J. Anal. Chem. **2020**, 92 (7), 5222–5230.
- 416(52) Clowers, B. H.; Belov, M. E.; Prior, D. C.; Danielson, W. F.; Ibrahim, Y.; Smith, R. D. *Anal. Chem.* **2008**, *80* (7), 2464–2473.
- 418(53) Groessl, M.; Graf, S.; Taylor, A.; Knochenmuss, R. 2015, 1–4.
- 419(54) Zheng, X.; Wojcik, R.; Zhang, X.; Ibrahim, Y. M.; Burnum-Johnson, K. E.; Orton, D. J.; Monroe, 420 M. E.; Moore, R. J.; Smith, R. D.; Baker, E. S. *Annu. Rev. Anal. Chem.* **2017**, *10* (1), 71–92.
- 421(55) Hines, K. M.; May, J. C.; McLean, J. A.; Xu, L. Anal. Chem. 2016, 88, 7329–7336.
- 422(56) Jackson, S. N.; Ugarov, M.; Post, J. D.; Egan, T.; Langlais, D.; Schultz, J. A.; Woods, A. S. *J. Am. Soc. Mass Spectrom.* **2008**, *19* (11), 1655–1662.
- 424(57) Leaptrot, K. L.; May, J. C.; Dodds, J. N.; McLean, J. A. Nat. Commun. 2019, 10 (1), 985.
- 425(58) Stauber, J.; MacAleese, L.; Franck, J.; Claude, E.; Snel, M.; Kaletas, B. K.; Wiel, I. M. V. D.;

Wisztorski, M.; Fournier, I.; Heeren, R. M. A. J. Am. Soc. Mass Spectrom. 2010, 21 (3), 338–347. Chughtai, K.; Jiang, L.; Greenwood, T. R.; Glunde, K.; Heeren, R. M. A. J. Lipid Res. 2013, 54 427(59) (2), 333–344.




Figure 1. **a)** A schematic drawing of the nano-DESI MSI source from ref⁴³. **b)** A photograph of the 444imaging platform, showing the custom-designed cart (1); vibrationally insulated platform (2); lock-in 445amplifier (3), and computer that controls the xyz stage (4). **c)** A zoomed-in photograph corresponding to 446the red dashed box in panel b. The XYZ stage (5), micro positioners (6), Dino-Lite microscope 7), 447capillary extension (8), primary capillary (9), spray capillary (10) and shear force probe (11) are also

448highlighted.




Figure 2. a) Mass spectra averaged over a linescan across the central region of a mouse uterine section 457(red dashed line) shown in the optical image. The spectrum acquired using QTOF is shown as positive 458signal and the spectrum acquired using an Orbitrap is shown as negative signal. Pink circles and blue 459diamonds denote [M+K]⁺ and [M+Na]⁺ ions, respectively. **b)** Pie chart showing the total number of 460species detected from the molecular profiling in positive mode with both platforms. **c)** Direct comparison 461of the number of species detected by molecular class with the QTOF and Orbitrap imaging platforms.




Figure 3. Representative nano-DESI ion images from mouse uterine sections collected using the new 465nano-DESI-QTOF platform (top row) and the traditional nano-DESI-orbitrap platform (bottom row). 466These data sets were collected using 7 Hz acquisition rate. Optical images of the uterine tissue sections 467highlighting their main components like myometrium (myo), stroma (S), luminal epithelium (LE) and 468glandular epithelium (GE) are included on the left side. The intensity scale changes from black (low) to 469yellow (high).




Figure 4. a) Direct comparison of the number of species in each molecular class detected in mouse 479uterine sections using the MS and IM-MS modes of the IM-QTOF instrument. **b)** Representative ion 480images of endogenous molecules of mobility separated ions using the nano-DESI-IM-QTOF platform 481(right column). Ion images collected without mobility separation are included in the left column for 482comparison. Optical images of the uterine tissue sections used for imaging experiments are shown in the 483first row. The intensity scale changes from black (low) to yellow (high).





Figure 5. a) Drift time vs. *m*/*z* plot of the species identified in the nano-DESI-IM-MSI data. **b)** Lipid 486classes separated by drift time in the *m*/*z* 760-880 region highlighted with the dashed box in panel. 487Triangles and circles denote [M+Na]⁺ and [M+K]⁺, respectively and the symbol colors indicate the lipid 488class of the molecule as indicated in the legend. The nomenclature used to indicate the individual species 489is AA:X, where AA denotes the acyl chain length and X denotes the number of double bonds. The colored 490lines highlight the series of homologous species differing by the number of double bonds; the number of 491double bonds for each species is indicated inside the corresponding marker.

495For Table of Contents Only



SUPPORTING INFORMATION

Nanospray Desorption Electrospray Ionization (nano-DESI) Mass Spectrometry Imaging of Drift Time-Separated Ions

Daisy Unsihuay,¹ Ruichuan Yin,¹ Daniela Mesa Sanchez,¹ Yingju Li,² Xiaofei Sun,² Sudhansu K. Dey,² Julia Laskin¹*

- 1. Department of Chemistry, Purdue University, West Lafayette, IN 47907, USA
- 2. Division of Reproductive Sciences, Cincinnati Children's Hospital Medical Centre and Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, OH, 45229, USA

Corresponding author: Julia Laskin, Tel: 765-494-5464, Email: jlaskin@purdue.edu




Figure S1. Representative line profiles of the species used for calculating the spatial resolution in all data sets. Yellow dotted lines drawn over ion images indicate the direction of the line profiles shown on the right side of every ion image. The black dotted lines shown in every line profile indicate the 0% and 100% of the chemical gradient. We estimated the spatial resolution by calculating the distance over which the signal intensity increases from 20 to 80% of the maximum value. Chemical gradients observed on the boundaries between S and LE cells were used to estimate the spatial resolution as they gave the sharpest features. **a)** Line profiles of PC(38:2) at m/z 836.6096 and MG(18:1) at m/z 379.2834 were used to estimate the spatial resolution of the Orbitrap and QTOF imaging platforms, respectively, at 7Hz acquisition rate. **b)** Line profiles of MG(18:1) at m/z 379.2834 were used to estimate the spatial resolution of the IM-QTOF platform operated in both MS mode and IM-MS modes at 1Hz acquisition rate.




Figure S2. Averaged mass spectra of adjacent line scans in the same tissue section at different acquisition rates 1Hz, 3Hz, 5Hz and 7Hz. S/N ratios at m/z 782.565 for each acquisition rate are indicated .




Figure S3. Lipid classes separated by drift time in the *m*/*z* 720-890 region highlighted with the dashed box in **Figure 5a**. Triangles, circles and squares denote [M+Na]⁺, [M+K]⁺ and [M+H]⁺ adducts, respectively and the symbol colors indicate the lipid class of the molecule as indicated in the legend. The nomenclature used to indicate the individual species is AA:X, where AA denotes the acyl chain length and X denotes the number of double bonds. The doted lines highlight the series of homologous species differing by the number of double bonds; the number of double bonds for each species is indicated inside the corresponding marker. Of note is that the isobaric species of [M+Na]⁺ and [M+H]⁺] adducts from the same lipid class were not separated in the mobility dimension and showed overlapping trend lines.




Figure S4. 2D IM-MS plot showing the presence of two possible isomers at m/z 325.211 separated in the drift time dimension at DT 26.83 ms and DT 25.87 ms. Ion images of the drift time-selected species are shown on the right side.




Figure S5. Separation of isobaric PE(40:4) from PC(P-38:3) in the 2D IM-MS plot. Drift time-selected ion images generated for each molecule are depicted on the right side.




Figure S6. 2D IM-MS plot showing the isobaric separation of a solvent peak at DT 30.62 from the endogenous molecule LPC(18:2) at DT 32.16 ms. The ion image corresponding to LPC (18:2) without drift time separation is included on the left side for comparison.

Table S1. Front Funnel Settings for the QTOF and IM-QTOF Mode experiments in Positive Mode

High Pressure	High Pressure	Trap funnel delta	Trap funnel RF	Trap funnel Exit
funnel delta (V)	funnel RF (V)	(V)	(V)	(V)
150	120	180	120	10

Table S2. Rear Funnel Settings for the IM-QTOF Mode experiments in Positive Mode

Rear funnel exit	30
IM Hex Delta	-6
IM Hex Entrance	28
Oct Entrance lens	21
Oct 1 DC	19.6
Lens1	19.5
Quad DC	19.3
Post Filter DC	19.2
Cell Entrance	19.1
Hex DC	19.2
Hex Delta	-5
Hex2 DC	14.2
Hex2 DV	-2
Hex3 DC	12.1
Ion Focus	10

Table S3. Drift Tube Settings for the IM-QTOF in Positive Mode

Drift Tube	Drift Tube Exit	Rear Funnel	Rear Funnel Exit
Entrance (V)	(V)	Entrance (V)	(V)
1571.9	224.1	218.2	30

Table S4. A complete list of annotated species for all data sets

			71		IM-	QTOF 1Hz
m/z	Name	Adduct	Orbitra p	QTOF	MS	IM-MS
136.0479	Creatinine	+ Na	X	X	X	X
137.0462	threonic acid	+ H		X	X	X
138.0522	L-Proline	+ Na	X	X	X	
140.0695	valine	+ Na	X	X	X	X
146.1168	Acetylcholine	+ H		X	X	
147.1125	L-Lysine	+ H	X	X	X	
148.0036	Taurine	+ Na	X	X	X	X
152.0217	Creatinine	+ K	X	X	X	X
153.9905	Maleamic acid	+ K	X			
154.0584	Creatine	+ Na	X	X	X	X
154.0834	L-Leucine	+ Na	X	X	X	X
156.042	valine	+ K	X	X	X	X
159.0274	threonic acid	+ Na	X	X	X	
160.133	3-ami-octaic acid	+ H	X	X	X	X
162.1121	Carnitine	+ H	X	X	X	X
163.9774	Taurine	+ K	X	X	X	X
166.0836	L-Phenylalanine	+ H	X	X	X	X
169.0582	L-Glutamine	+ Na	X	X	X	X
169.9855	Imiaspartic acid	+ K	X	X	X	X
170.0323	Creatine	+ K	X	X	X	X
175.0013	threonic acid	+ K	X	X	X	X
175.1186	L-Arginine	+ H	X	X	X	X
176.0401	Guanidisuccinic Acid	+ H	X	X	X	X
178.0582	Histidine	+ Na	X	X	X	
182.0569	Proline betaine	+ H	X	X	X	X
184.094	Carnitine	+ Na	X	X	X	X
185.0322	L-Glutamine	+ K	X	X	X	X
188.0677	L-Phenylalanine	+ Na	X	X	X	X
194.0305	Histidine	+ K		X	X	
195.0025	Glycerol 2-phosphate	+ Na	X	X	X	
200.0679	Carnitine	+ K	X	X	X	X
203.0522	α-D-Glucose	+ Na	X	X	X	X
204.1229	CAR(2:0)	+ H	X	X	X	X
207.0134	Phospho-L-serine	+ Na	X	X	X	X
214.0585	Argininic acid	+ K		X	X	

217.0678							
225.0341 Cysteinyl-Cysteine	217.0678	D-Glucoside	+ Na	X	X	X	X
226.1045	219.0261	α-D-Glucose	+ K	X	X	X	X
227.0789	225.0341	Cysteinyl-Cysteine	+ H	X			
238.0446 Glycerylphosphorylethalamine + Na	226.1045	CAR(2:0)	+ Na	X	X	X	X
240.1206	227.0789	L-Tryptophan	+ Na	X	X	X	
242.0781 CAR(2:0) + K X X X 246.1782 Lysyl-Valine + H X X X 254.1351 Butyryl-L-camitine + K X X X 258.1097 Glycerophosphocholine + H X X X X 266.15 Lysyl-Proline + Na X	238.0446	Glycerylphosphorylethalamine	+ Na	X	X	X	X
246.1782 Lysyl-Valine + H X X X 254.0181 Glycerylphosphorylethalamine + K X X X 254.1351 Butyryl-L-carnitine + Na X X X 258.1097 Glycerophosphocholine + H X X X X 266.15 Lysyl-Proline + Na X	240.1206	Propionyl-L-carnitine	+ Na	X			X
254.0181 Glycerylphosphorylethalamine	242.0781	CAR(2:0)	+ K	X	X	X	X
254.1351 Butyryl-L-carnitine	246.1782	Lysyl-Valine	+ H	X	X	X	X
258.1097 Glycerophosphocholine + H X X X 266.15 Lysyl-Proline + Na X X X X 268.1512 pivaloylcarnitine + Na X X X X 277.1043 Glutamyl-glutamic acid + H X X X X 280.0919 Glycerophosphocholine + Na X	254.0181	Glycerylphosphorylethalamine	+ K		X	X	X
266.15 Lysyl-Proline + Na X	254.1351	Butyryl-L-carnitine	+ Na		X		X
268.1512 pivaloylcarnitine + Na X<	258.1097	Glycerophosphocholine	+ H	X	X	X	X
277.1043 Glutamyl-glutamic acid + H X X X 280.0919 Glycerophosphocholine + Na X X X X 282.1461 leucil-glutamine + Na X X X X 284.1252 pivaloylcarnitine + K X X X X 291.0695 Inosine + Na X X X X X 295.1302 Glutamylphenylalanine + H X	266.15	Lysyl-Proline	+ Na	X	X	X	X
280.0919 Glycerophosphocholine + Na X <t< td=""><td>268.1512</td><td>pivaloylcarnitine</td><td>+ Na</td><td>X</td><td>X</td><td>X</td><td>X</td></t<>	268.1512	pivaloylcarnitine	+ Na	X	X	X	X
282.1461 leucil-glutamine + Na X </td <td>277.1043</td> <td>Glutamyl-glutamic acid</td> <td>+ H</td> <td>X</td> <td>X</td> <td>X</td> <td></td>	277.1043	Glutamyl-glutamic acid	+ H	X	X	X	
282.1461 leucil-glutamine + Na X </td <td>280.0919</td> <td>Glycerophosphocholine</td> <td>+ Na</td> <td>X</td> <td>X</td> <td>X</td> <td>X</td>	280.0919	Glycerophosphocholine	+ Na	X	X	X	X
284.1252 pivaloylcarnitine + K X X X 291.0695 Inosine + Na X X X X 295.1302 Glutamylphenylalanine + H X X X X 296.0657 Glycerophosphocholine + K X X X X 303.2288 FA(18:2) + Na X X X X 305.2445 FA(18:1) + Na X X X X 307.0437 Inosine + K X X X X 316.9822 2-Deoxy-D-ribose 1,5-bisphosphate + Na X X X 317.244 FA(19:0) + Na X X X 317.2591 FA(19:1) + H X X X 317.2592 FA(19:1) + H X X X 322.0546 Guanosine + K X X X 325.2108 FA(20:5) + Na </td <td>282.1461</td> <td></td> <td>+ Na</td> <td>X</td> <td>X</td> <td>X</td> <td>X</td>	282.1461		+ Na	X	X	X	X
291.0695 Inosine + Na X	284.1252		+ K		X	+ +	X
295.1302 Glutamylphenylalanine + H X X X 296.0657 Glycerophosphocholine + K X X X X 303.2288 FA(18:2) + Na X X X X 305.2445 FA(18:1) + Na X X X X 307.0437 Inosine + K X X X X 316.9822 2-Deoxy-D-ribose 1,5-bisphosphate + Na X X X X 317.244 FA(19:0) + Na X X X X 319.2591 FA(19:1) + H X X X X 322.0546 Guanosine + K X X X X 323.039 Xanthosine + Na X X X X 325.2108 FA(20:5) + Na X X X X 327.2278 FA(20:4) + Na X X X X	291.0695	1 5	+ Na	X	X	X	X
296.0657 Glycerophosphocholine + K X X X 303.2288 FA(18:2) + Na X X X 305.2445 FA(18:1) + Na X X X 307.0437 Inosine + K X X X X 316.9822 2-Deoxy-D-ribose 1,5-bisphosphate + Na X X X X 317.244 FA(19:0) + Na X X X X 319.2591 FA(19:1) + H X X X X 319.2591 FA(19:1) + H X X X X 322.0546 Guanosine + K X X X X 325.2108 FA(20:5) + Na X X X X X 325.2342 MG(14:0) + Na X X X X X X X X X X X X X X <td< td=""><td>295.1302</td><td>Glutamylphenylalanine</td><td>+ H</td><td></td><td>X</td><td></td><td>X</td></td<>	295.1302	Glutamylphenylalanine	+ H		X		X
303.2288 FA(18:2) + Na X X X 305.2445 FA(18:1) + Na X X X 307.0437 Inosine + K X X X X 316.9822 2-Deoxy-D-ribose 1,5-bisphosphate + Na X X X X 317.244 FA(19:0) + Na X X X X 319.2591 FA(19:1) + H X X X X 322.0546 Guanosine + K X X X X 323.039 Xanthosine + Na X X X X 325.2108 FA(20:5) + Na X X X X 325.2342 MG(14:0) + Na X X X X 327.2278 FA(20:4) + Na X X X X 341.2434 Allopregnalone + Na X X X X 345.2	296.0657		+ K	X	X	X	X
307.0437	303.2288		+ Na	X	X	X	
316.9822 2-Deoxy-D-ribose 1,5-bisphosphate + Na X X X 317.244 FA(19:0) + Na X X X 319.2591 FA(19:1) + H X X X 322.0546 Guanosine + K X X 323.039 Xanthosine + Na X X 325.2108 FA(20:5) + Na X X 325.2342 MG(14:0) + Na X X X 327.2278 FA(20:4) + Na X X X X 332.9558 2-Deoxy-D-ribose 1,5-bisphosphate + K X X X X 341.2434 Allopregnalone + Na X X X X 345.2731 FA(21:0) + Na X X X X 353.244 FA(22:5) + Na X X X X 355.2584 FA(22:4) + Na X X X X 365.2443 3-oxo-eicosaic acid + K X X X <td>305.2445</td> <td>FA(18:1)</td> <td>+ Na</td> <td>X</td> <td></td> <td>X</td> <td></td>	305.2445	FA(18:1)	+ Na	X		X	
316.9822 bisphosphate + Na X	307.0437	Inosine	+ K	X	X	X	X
319.2591 FA(19:1) + H X X 322.0546 Guanosine + K X X 323.039 Xanthosine + Na X 325.2108 FA(20:5) + Na X 325.2342 MG(14:0) + Na X 327.2278 FA(20:4) + Na X X 332.9558 2-Deoxy-D-ribose 1,5-bisphosphate + K X X X 341.2434 Allopregnalone + Na X X X 345.2731 FA(21:0) + Na X X X 353.249 MG(16:1) + Na X X X 353.244 FA(22:5) + Na X X X 355.2584 FA(22:4) + Na X X X 365.2443 3-oxo-eicosaic acid + K X X X	316.9822		+ Na		X	X	X
322.0546 Guanosine + K X X 323.039 Xanthosine + Na X X 325.2108 FA(20:5) + Na X X 325.2342 MG(14:0) + Na X X X 327.2278 FA(20:4) + Na X X X X 332.9558 2-Deoxy-D-ribose 1,5-bisphosphate + K X X X X 341.2434 Allopregnalone + Na X X X X 345.2731 FA(21:0) + Na X X X X 351.249 MG(16:1) + Na X X X X 353.244 FA(22:5) + Na X X X X 355.2584 FA(22:4) + Na X X X X 365.2443 3-oxo-eicosaic acid + K X X X X	317.244	FA(19:0)	+ Na	X	X	X	
323.039 Xanthosine + Na X 325.2108 FA(20:5) + Na X 325.2342 MG(14:0) + Na X 327.2278 FA(20:4) + Na X X 332.9558 2-Deoxy-D-ribose 1,5-bisphosphate + K X X X 341.2434 Allopregnalone + Na X X X 345.2731 FA(21:0) + Na X X X 351.249 MG(16:1) + Na X X X 353.244 FA(22:5) + Na X X X 355.2584 FA(22:4) + Na X X X 365.2443 3-oxo-eicosaic acid + K X X X	319.2591	FA(19:1)	+ H	X	X	X	
325.2108 FA(20:5) + Na X 325.2342 MG(14:0) + Na X 327.2278 FA(20:4) + Na X X 327.2278 FA(20:4) + Na X X X 332.9558 2-Deoxy-D-ribose 1,5-bisphosphate + K X X X X 341.2434 Allopregnalone + Na X X X X 345.2731 FA(21:0) + Na X X X X 351.249 MG(16:1) + Na X X X X 353.244 FA(22:5) + Na X X X X 355.2584 FA(22:4) + Na X X X X 365.2443 3-oxo-eicosaic acid + K X X X X	322.0546	Guanosine	+ K		X	X	
325.2342 MG(14:0) + Na X 327.2278 FA(20:4) + Na X X X 332.9558 2-Deoxy-D-ribose 1,5-bisphosphate + K X X X X 341.2434 Allopregnalone + Na X X X X 345.2731 FA(21:0) + Na X X X 351.249 MG(16:1) + Na X X X 353.244 FA(22:5) + Na X X X 355.2584 FA(22:4) + Na X X X 365.2443 3-oxo-eicosaic acid + K X X X X	323.039	Xanthosine	+ Na	X			
327.2278 FA(20:4) + Na X X X 332.9558 2-Deoxy-D-ribose 1,5-bisphosphate + K X X X X 341.2434 Allopregnalone + Na X X X X 345.2731 FA(21:0) + Na X X X 351.249 MG(16:1) + Na X X X 353.244 FA(22:5) + Na X X X 355.2584 FA(22:4) + Na X X X 365.2443 3-oxo-eicosaic acid + K X X X	325.2108	FA(20:5)	+ Na	X			X
332.9558 2-Deoxy-D-ribose 1,5-bisphosphate + K X X X X 341.2434 Allopregnalone + Na X X X X 345.2731 FA(21:0) + Na X X X 351.249 MG(16:1) + Na X X X 353.244 FA(22:5) + Na X X X 355.2584 FA(22:4) + Na X X X 365.2443 3-oxo-eicosaic acid + K X X X	325.2342	MG(14:0)	+ Na	X			
332.9558 bisphosphate + K X X X X 341.2434 Allopregnalone + Na X X X X 345.2731 FA(21:0) + Na X X X X 351.249 MG(16:1) + Na X X X X 353.244 FA(22:5) + Na X X X X 355.2584 FA(22:4) + Na X X X X 365.2443 3-oxo-eicosaic acid + K X X X X	327.2278	FA(20:4)	+ Na	X	X	X	X
345.2731 FA(21:0) + Na X X X 351.249 MG(16:1) + Na X 353.244 FA(22:5) + Na X X X 355.2584 FA(22:4) + Na X X X X 365.2443 3-oxo-eicosaic acid + K X X X X	332.9558	,	+ K	X	X	X	X
351.249 MG(16:1) + Na X 353.244 FA(22:5) + Na X X X 355.2584 FA(22:4) + Na X X X 365.2443 3-oxo-eicosaic acid + K X X X	341.2434		+ Na	X	X	X	X
353.244 FA(22:5) + Na X X X X 355.2584 FA(22:4) + Na X X X X 365.2443 3-oxo-eicosaic acid + K X X X X	345.2731	FA(21:0)	+ Na	X	X	X	X
355.2584 FA(22:4) + Na X X X X 365.2443 3-oxo-eicosaic acid + K X X X X	351.249	MG(16:1)	+ Na	X			
365.2443 3-oxo-eicosaic acid + K X X X X	353.244	FA(22:5)	+ Na	X	X	X	X
	355.2584	FA(22:4)	+ Na	X	X	X	X
367.2027 FA(22:6) + K X X X X	365.2443	3-oxo-eicosaic acid	+ K	X	X	X	X
	367.2027	FA(22:6)	+ K	X	X	X	X

367.2234	MG(16:1)	+ K	X	X	X	
367.2587	3hydroxy-eicosaic acid	+ K	X	X	X	X
369.2392	MG(16:0)	+ K	X	X	X	X
373.2107	MG(O-18:5)	+ K	X			X
377.2653	MG(18:2)	+ Na	X	X	X	X
378.2949	N-palmitoyl valine	+ Na	X	X	X	X
379.2834	MG(18:1)	+ Na	X	X	X	X
381.297	MG(18:0)	+ Na	X	X	X	
393.2386	MG(18:2)	+ K	X	X	X	X
395.2549	MG(18:1)	+ K	X	X	X	X
395.2762	15-HETE-G	+ H	X	X	X	X
397.2706	MG(18:0)	+ K	X	X	X	X
400.3417	CAR(16:0)	+ H	X	X	X	X
401.2653	MG(20:4)	+ Na	X	X	X	X
403.281	MG(20:3)	+ Na	X	X	X	X
405.2855	MG(20:2)	+ Na		X	X	
407.3122	MG(20:1)	+ Na	X	X	X	X
408.2867	Arachidoyl glycine	+ K	X	X	X	X
417.2379	MG(20:4)	+ K	X	X	X	X
419.2555	MG(20:3)	+ K	X	X	X	X
422.3234	CAR(16:0)	+ Na	X	X	X	X
425.2634	MG(22:6)	+ Na	X	X	X	X
427.2796	MG(22:5)	+ Na	X	X	X	X
429.2966	MG(22:4)	+ Na	X	X	X	X
441.2349	MG(22:6)	+ K	X	X	X	X
443.2503	MG(22:5)	+ K		X	X	X
445.2694	MG(22:4)	+ K	X	X	X	X
457.2344	15-HETE-G	+ K	X			
478.3286	LPC(O-16:2)	+ H	X	X	X	
504.3034	LPE(18:0)	+ Na	X	X	X	
504.3421	LPC(O-16:0)	+ Na	X	X	X	
506.3569	LPC(P-18:1)	+ H	X	X	X	
507.9989	Adenosine triphosphate (ATP)	+ H	X	X	X	
518.3212	LPC(16:0)	+ Na	X	X	X	X
524.2762	LPE(20:4)	+ Na	X	X	X	
524.37	LPC(18:0)	+ H		X	X	
534.2952	LPC(16:0)	+ K	X	X	X	X
542.3208	LPC(18:2)	+ Na	X			X
544.3391	LPC(18:1)	+ Na	X	X	X	X
546.3524	LPC(18:0)	+ Na	X	X	X	X
548.274	LPE(22:6)	+ Na	X	X	X	

558.2979	LPC(18:2)	+ K	X	X	X	X
				+	+	Λ
560.3105	LPC(18:1)	+ K	X	X	X	
562.3261	LPC(18:0)	+ K	X	X	X	X
566.3205	LPC(20:4)	+ Na	X	X	X	
570.2557	LPE(22:6)	+ 2Na- H	X	X	X	
576.2693	Vignatic acid A	+ Na	X	X	X	X
592.2477	Vignatic acid A	+ K		X	X	X
615.4946	DG(34:2)	+ Na	X	X	X	X
617.5104	DG(34:1)	+ Na	X	X	X	
631.4707	DG(34:2)	+ K	X	X	X	X
633.4832	DG(34:1)	+ K	X	X	X	X
639.4948	DG(36:4)		X	X	X	
641.5098	DG(36:3)	+ Na	X	X	X	X
643.5258	DG(36:2)	+ Na	X	X	X	X
645.5406	DG(36:1)	+ Na	X	X	X	
657.4831	DG(36:3)	+ K	X	X	X	X
659.4994	DG(36:2)	+ K	X	X	X	X
663.4943	DG(38:6)	+ Na	X	X	X	X
665.5003	DG(38:5)	+ Na		X	X	X
667.5258	DG(38:4)	+ Na	X	X	X	X
669.5409	DG(38:3)	+ Na	X	X	X	X
671.5563	DG(38:2)	+ Na	X	X	X	
672.4199	PC(16:0/9:0(CHO))	+ Na	X	X		
681.4771	DG(38:5)	+ K		X	X	X
683.4941	DG(38:4)	+ K	X	X	X	X
685.5144	DG(38:3)	+ K		X	X	X
689.5099	DG(40:7)	+ Na	X	X	X	X
691.5189	DG(40:6)	+ Na	X	X	X	X
693.5374	DG(40:5)	+ Na	X	X	X	X
703.4607	DG(40:8)	+ K		X	X	X
703.5748	SM(d34:1)	+ H	X	X	X	
705.4845	DG(40:7)	+ K	X	X	X	X
725.5557	SM(d34:1)	+ Na	X	X	X	X
727.5636	SM(d34:0)	+ Na	X	X	X	
728.5189	PC(30:0)	+ Na	X	X	X	X
732.4204	PC(18:0/9:0(COOH))	+ K	X			
734.5679	PC(32:0)	+ H	X	X	X	
739.5133	SM(d34:2)	+ K		X	X	X
741.5279	SM(d34:1)	+ K	X	X	X	X
742.5666	PC(O-32:0)	+ Na	X	X	X	X
744.4967	PC(30:0)	+ K	X	X	X	X

746.508	PE(O-36:5)	+ Na	X	X	X	X
754.5344	PC(32:1)	+ Na	X	X	X	X
754.5344	PC(34:4)	+ H	X	X	X	X
756.5499	PC(32:0)	+ Na	X	X	X	X
756.5499	PC(34:3)	+ H	X	X	X	X
758.5596	PC(34:2)	+ H	X	X	X	X
760.5833	PC(34:1)	+ H	X	X	X	X
762.4923	PE(36:4)	+ Na	X			X
766.5344	PE(36:2)	+ Na	X			X
766.5344	PE(38:5)	+ H	X			X
766.567	PC(P-34:1)	+ Na	X	X	X	X
766.567	PC(P-36:4)	+ H	X	X	X	X
768.4931	PC(32:2)	+ K	X			
768.5498	PE(36:1)	+ Na	X	X	X	X
768.5498	PE(38:4)	+ H	X	X	X	X
768.5865	PC(P-34:0)	+ Na	X	X	X	X
768.5865	PC(P-36:3)	+ H	X	X	X	X
770.509	PC(32:1)	+ K	X	X	X	X
772.525	PC(32:0)	+ K	X	X	X	X
774.5352	PE(P-38:4)	+ Na	X	X	X	X
778.5358	PC(34:3)	+ Na	X	X	X	X
778.5358	PC(36:6)	+ H	X	X	X	X
780.5503	PC(34:2)	+ Na	X	X	X	X
780.5503	PC(36:5)	+ H	X	X	X	X
782.5658	PC(34:1)	+ Na	X	X	X	X
784.5759	PC(34:0)	+ Na	X	X	X	X
786.4988	PE(38:6)	+ Na	X	X	X	X
786.5975	PC(36:2)	+ H	X	X	X	X
788.5591	PC(P-36:4)	+ Na	X			X
788.6169	PC(36:1)	+ H	X	X	X	X
790.5339	PE(38:4)	+ Na	X			X
790.5688	PC(P-36:3)	+ Na	X	X	X	X
790.5688	PC(P-38:6)	+ H	X	X	X	X
794.5648	PE(38:2)	+ Na	X			X
794.602	PC(P-36:1)	+ Na	X	X	X	X
794.602	PC(P-38:4)	+ H	X	X	X	X
796.5215	PC(34:2)	+ K	X	X	X	X
796.5786	PE(38:1)	+ Na	X			
798.5397	PC(34:1)	+ K	X	X	X	X
802.5345	PC(36:5)	+ Na	X	X	X	X
802.5345	PC(38:8)	+ H	X	X	X	X

004 5502	DC(2C,4)	l No	v	v	v	v
804.5503	PC(36:4)	+ Na	X	X	X	X
804.5503	PC(38:7)	+ H	X	X	X	X
806.5084	PE(38:4)	+ K	X	X	X	X
806.5633	PC(36:3)	+ Na	X	X	X	X
806.5633	PC(38:6)	+ H	X	X	X	X
808.5807	PC(36:2)	+ Na	X	X	X	X
808.5807	PC(38:5)	+ H	X	X	X	X
809.649	SM(d40:1)	+ Na	X	X	X	
810.5963	PC(36:1)	+ Na	X	X	X	X
812.5202	PE(40:7)	+ Na	X			
812.5583	PC(P-38:6)	+ Na	X	X	X	X
812.6097	PC(36:0)	+ Na	X	X	X	
812.6097	PC(38:3)	+ H	X	X	X	
813.687	SM(d42:2)	+ H	X	X	X	
814.5326	PE(40:6)	+ Na	X			X
814.5699	PC(P-38:5)	+ Na	X			X
816.5476	PE(40:5)	+ Na	X			X
816.5884	PC(P-38:4)	+ Na	X	X	X	X
816.5884	PC(P-40:7)	+ H	X	X	X	X
818.5097	PC(36:5)	+ K	X	X	X	X
818.5637	PE(40:4)	+ Na	X			X
818.5637	PE(42:7)	+ H	X			X
818.6019	PC(P-38:3)	+ Na	X	X	X	X
818.6019	PC(P-40:6)	+ H	X	X	X	X
820.5236	PC(36:4)	+ K	X	X	X	X
822.5372	PC(36:3)	+ K	X	X	X	X
824.5544	PC(36:2)	+ K	X	X	X	X
826.5699	PC(36:1)	+ K	X	X	X	X
828.5498	PC(38:6)	+ Na	X	X	X	X
828.5498	PC(40:9)	+ H	X	X	X	X
830.5577	PC(38:5)	+ Na	X	X	X	X
832.5802	PC(38:4)	+ Na	X	X	X	X
832.5802	PC(40:7)	+ H	X	X	X	X
834.5947	PC(38:3)	+ Na	X	X	X	X
834.5947	PC(40:6)	+ H	X	X	X	X
835.665	SM(d42:2)	+ Na	X	X	X	X
836.6096	PC(38:2)	+ Na	X	X	X	X
836.6096	PC(40:5)	+ H	X	X	X	X
838.6241	PC(38:1)	+ Na	X	X	X	<u> </u>
838.6241	PC(38:4)	+ H	X	X	X	
842.5931	PC(P-40:5)	+ Na	X	X	X	X

844.5249	PC(38:6)	+ K	X	X	X	X
844.6105	PC(P-40:4)	+ Na	X	X	X	X
844.6105	PC(P-42:7)	+ H	X	X	X	X
846.5317	PC(38:5)	+ K	X	X	X	X
848.555	PC(38:4)	+ K	X	X	X	X
850.5656	PC(38:3)	+ K	X	X	X	X
851.6318	SM(d42:2)	+ K	X	X	X	
856.5757	PC(40:6)	+ Na	X	X	X	X
856.5757	PC(42:9	+ H	X	X	X	X
858.5871	PC(42:8)	+ H	X	X	X	X
858.5915	PC(40:5)	+ Na	X	X	X	X
860.6047	PC(42:7)	+ H	X	X	X	X
860.6105	PC(40:4)	+ Na	X	X	X	X
868.5189	PC(40:8)	+ K	X	X	X	X
870.536	PC(40:7)	+ K	X	X	X	X
872.5506	PC(40:6)	+ K	X	X	X	X
880.5669	PC(P-42:8)	+ K	X	X	X	X